Literature DB >> 9127646

Placental cytokines and the pathogenesis of preeclampsia.

K P Conrad1, D F Benyo.   

Abstract

The authors explore the hypothesis that tumor necrosis factor-alpha (TNF-alpha) and possibly other inflammatory cytokines are overproduced by the placenta in response to local ischemia/hypoxia contributing to increased plasma levels, and subsequent endothelial activation and dysfunction in the pregnancy disorder, preeclampsia. It is widely held that inadequate trophoblast invasion and physiologic remodeling of spiral arteries initiate placental ischemia/hypoxia in preeclampsia. Furthermore, focal areas of placental hypoxia have been implicated in the production of "toxic" factor(s) by the placenta, which circulate and cause maternal disease. Placental trophoblast cells and fetoplacental macrophages normally produce TNF-alpha and interleukin-1 (IL-1), which are capable of producing endothelial cell activation and dysfunction. Hypoxia has recently been reported to increase TNF-alpha and IL-1 production by term villous explants from the human placenta. Placental cells also express erythropoietin (EPO), which is the prototype molecule for transcriptional regulation by hypoxia in mammals. Interestingly, TNF-alpha and IL-1 have DNA sequence homologous or nearly homologous to the hypoxia-responsive enhancer element of the EPO gene, thus providing a potential, but as of yet, untested molecular link between placental hypoxia and stimulation of cytokine production. Inflammatory cytokines overproduced by the placenta in response to hypoxia may then lead to increased plasma levels and endothelial activation and dysfunction in preeclampsia. The purpose of this short review is to critically evaluate the hypothesis that placental cytokines contribute to the pathogenesis of preeclampsia. Of note, the etiology of the disease presumably related to deficient trophoblast invasion is beyond the scope of this work.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9127646     DOI: 10.1111/j.1600-0897.1997.tb00222.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  125 in total

Review 1.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Pathophysiology and maternal biologic markers of preeclampsia.

Authors:  Jacques Massé; Yves Giguère; Abdelaziz Kharfi; Joël Girouard; Jean-Claude Forest
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

3.  IL-6-induced pathophysiology during pre-eclampsia: potential therapeutic role for magnesium sulfate?

Authors:  Babbette Lamarca; Justin Brewer; Kedra Wallace
Journal:  Int J Interferon Cytokine Mediat Res       Date:  2011-07-01

4.  17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model.

Authors:  Lorena M Amaral; Denise C Cornelius; Ashlyn Harmon; Janae Moseley; James N Martin; Babbette LaMarca
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

5.  Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2012-08

6.  The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2010-04

7.  Hypertension in response to CD4(+) T cells from reduced uterine perfusion pregnant rats is associated with activation of the endothelin-1 system.

Authors:  Kedra Wallace; Sarah Novotny; Judith Heath; Janae Moseley; James N Martin; Michelle Y Owens; Babbette LaMarca
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-05-30       Impact factor: 3.619

8.  TREM-1 expression is increased in human placentas from severe early-onset preeclamptic pregnancies where it may be involved in syncytialization.

Authors:  Ratana Lim; Gillian Barker; Martha Lappas
Journal:  Reprod Sci       Date:  2013-09-11       Impact factor: 3.060

9.  Role of IL-6 -174(G/C) promoter polymorphism in the etiology of early-onset preeclampsia.

Authors:  Sabnavis Sowmya; Aruna Ramaiah; Pratibha Nallari; Akka Jyothy; Ananthapur Venkateshwari
Journal:  Inflamm Res       Date:  2015-04-28       Impact factor: 4.575

10.  Serum levels of neopterin and interleukin-2 receptor in women with severe preeclampsia.

Authors:  Ilknur Kaleli; Babur Kaleli; Melek Demir; Basak Yildirim; Nural Cevahir; Suleyman Demir
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.